News
-
-
PRESS RELEASE
EQS-Adhoc: Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
Formycon AG announces positive CHMP opinion from EMA for Aflibercept-Biosimilar FYB203 (AHZANTIVE®/ Baiama®) as a treatment for retinal diseases. Market approval expected by January 2025 -
-
PRESS RELEASE
Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard
Formycon extends CEO contract until 2027. Receives admission to trading in Frankfurt Stock Exchange's Prime Standard. Company's biosimilars contribute to healthcare accessibility and cost reduction -
-
-
-
PRESS RELEASE
Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
Formycon publishes study results in peer-reviewed journal analyzing biosimilar candidate FYB206 and Keytruda, showing high similarity in structure and function. Results support ongoing clinical trials -
-
PRESS RELEASE
Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH releases an update on Formycon AG, with analyst Simon Scholes reiterating a BUY rating and raising the price target from EUR 80 to EUR 82. The approval of the biosimilar FYB202 in the EU and US contributes to the positive outlook on Formycon's market share prospects
